Welcome to our dedicated page for Novonix SEC filings (Ticker: NVNXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NOVONIX Limited (NVNXF) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. NOVONIX files Form 6-K current reports under the Securities Exchange Act of 1934, identified by Commission File Number 001-41208. These filings typically incorporate Australian Securities Exchange (ASX) documents and other materials that describe changes in NOVONIX’s securities, governance, and corporate actions.
Recent NOVONIX 6-K filings reference ASX forms such as Appendix 2A (Application for quotation of securities), Appendix 3H (Notification of cessation of securities), and Appendix 3X (Initial Director’s Interest Notice). Through these exhibits, investors can track events including new share quotations, cessation of securities, and initial disclosures of director interests. Other 6-Ks attach ASX announcements related to board appointments and other corporate developments.
For NVNXF investors, these filings complement company news releases that discuss NOVONIX’s battery materials and technology activities, including synthetic graphite projects in Chattanooga, Tennessee, technology licensing arrangements, and financing transactions. While detailed financial statements and risk discussions are typically provided in annual and periodic reports, the 6-Ks offer interim updates on material information that NOVONIX chooses to furnish to the SEC.
On this page, Stock Titan surfaces NOVONIX’s SEC submissions as they appear on EDGAR and pairs them with AI-powered summaries to explain the practical meaning of each filing. This can help readers quickly understand whether a filing relates to new securities being quoted, changes in existing securities, director interest notices, or other corporate announcements. Users interested in insider-related disclosures can review exhibits such as Appendix 3X, while those focused on capital structure can examine Appendices 2A and 3H and their associated descriptions.
Novonix Limited reported a small increase in its share count after performance rights converted into ordinary shares. The company applied for quotation of 2,177 NVX ordinary fully paid shares on ASX, issued on 3 March 2026 from options or other convertible securities under an employee incentive scheme.
These new shares form part of an existing quoted class. Following this quotation, the company’s quoted ordinary shares total 860,913,164, alongside unquoted performance rights, options, and convertible notes that remain outstanding.
Novonix Limited filed a Form 6-K furnishing several Australian Appendix 3Y notices that update directors’ shareholdings after equity awards vested. For director Robert Natter, 120,594 share rights vested into 120,594 ordinary shares, reported as an indirect interest.
Director Anthony Bellas also saw 120,594 share rights vest into 120,594 ordinary shares, increasing his indirect holding via Loch to 2,398,145 ordinary shares, alongside other existing holdings. Directors Sharan Burrow, Ron Edmonds, Jean Oelwang and Nicholas Liveris reported higher ordinary share holdings following the issue of shares on vesting of share rights, with no trades during a closed period.
NOVONIX Limited reported the issue of 7,704,361 unquoted performance rights (ASX code NVXAD) under its employee incentive scheme. These rights are in an existing, unquoted class and are not intended to be listed on the ASX.
Following this grant, NOVONIX has 860,910,987 ordinary fully paid shares on issue, alongside various unquoted securities including 25,092,989 performance rights in total, options, share rights, and convertible notes. The company confirms the issue was made under an exception in ASX Listing Rule 7.2, meaning separate security holder approval was not required.
NOVONIX Limited reports its 2025 results, with revenue of $5,617,119, down 4%, and a net loss of $92,725,187, 24% lower than the prior year’s loss. Net tangible assets per security fell to $0.18 from $0.22. No dividends were paid or declared for 2025 or 2024.
The company ended 2025 with $79.9 million in cash, cash equivalents and short-term investments but continues to post significant operating cash outflows and discloses material uncertainty about its ability to continue as a going concern. NOVONIX has a $100 million U.S. Department of Energy grant, a conditional DOE loan commitment of up to $754.8 million, and a $103 million U.S. tax credit allocation to support its Chattanooga anode materials build-out.
Management also highlights a binding term sheet, signed after year-end, for the proposed sale of its Battery Technology Solutions business, which currently generates all revenue. If completed, NOVONIX expects to focus on establishing a vertically integrated synthetic graphite supply chain in North America.
NOVONIX Limited has issued 1,008,567 new ordinary fully paid shares (ASX code NVX) following the exercise or conversion of existing share rights (NVXAB). These additional shares are in a class already quoted on the ASX and rank equally with existing ordinary shares from the issue date of February 27, 2026.
The consideration for these shares is non-cash, with an estimated value of AUD 0.335 per share. After this issuance, NOVONIX has 860,910,987 ordinary fully paid shares on issue, alongside unquoted performance rights, options and convertible notes.
NOVONIX Limited files its annual report on Form 20‑F, highlighting a capital-intensive growth plan, significant losses and substantial funding needs. The company reported a net loss of $84.5 million for 2025 and held $79.9 million in cash, cash equivalents and short‑term investments, alongside net current assets of $3.9 million. Management warns of material uncertainty about its ability to continue as a going concern.
NOVONIX is scaling synthetic graphite anode production at its Riverside facility in Chattanooga using proprietary furnace technology and long‑term offtake relationships with Panasonic Energy and PowerCo, but faces equipment delays, technology scale‑up risk and dependence on limited suppliers such as Harper and select needle coke producers. It has a $100 million DOE grant and a conditional DOE ATVM loan commitment of up to $754.8 million, both requiring significant cost sharing and strict compliance, plus a $103 million 48C tax credit allocation.
The company has entered a binding term sheet, subject to definitive agreements and conditions, to sell its Battery Technology Solutions business, which currently generates all revenue; after a divestiture, NOVONIX would have no revenue until its anode materials business scales. The filing details extensive risk factors spanning funding, customer concentration, graphite market dynamics, regulatory compliance and cybersecurity.
NOVONIX Limited filed an update announcing the timing of its 2026 Annual General Meeting. The AGM is scheduled for Wednesday, 15 April 2026 at 9:00am (AEST). The meeting details and agenda will be provided later in a formal Notice of Meeting sent to shareholders.
The company also set a cut-off for new board candidates. Nominations for persons to be considered for election as a director at the AGM must reach NOVONIX’s registered office by 5:00pm (AEST) on Wednesday, 25 February 2026. This notice complies with the company’s constitution and ASX Listing Rule 3.13.1.
NOVONIX Limited has entered into a binding term sheet to sell its NOVONIX Battery Technology Solutions Inc. business in Nova Scotia to former CEO Dr. Chris Burns. The deal is structured as a share sale for US$1.00, including all BTS assets and liabilities.
NOVONIX will retain a 15% non-dilutable equity stake in the buyer’s cathode business and BTS is expected to hold US$2 million in cash at closing, subject to customary adjustments. NOVONIX will provide transition services and license trademarks through at least 30 September 2026, further concentrating its strategy on a vertically integrated synthetic graphite supply chain in North America. Completion depends on definitive agreements and customary closing conditions.
NOVONIX Limited highlighted final U.S. Department of Commerce determinations that would sharply raise trade barriers on Chinese battery-grade graphite. Combined antidumping and countervailing duties on anode active materials imported from China are set to total at least 160%, subject to a final affirmative ruling by the U.S. International Trade Commission expected in March 2026.
Specific measures include a 93.5% antidumping duty on imports from certain Chinese companies, a 102.72% China-wide antidumping duty on all other exporters, and countervailing duties of 66.82%–66.86% on imports from Chinese producers. These duties will remain in place unless revoked and will be reviewed every five years.
The duties cover a wide range of synthetic and natural anode graphite products used in lithium-ion batteries. NOVONIX’s CEO said these moves help restore fair competition, support U.S. domestic battery material production, and materially enhance NOVONIX’s competitive position as it scales synthetic graphite production in North America.
NOVONIX Limited has reported the lapse of 139,547 NVXAD performance rights. These rights ceased on February 2, 2026 because the conditions attached to them were not met or had become incapable of being satisfied. No consideration was paid in connection with this cessation.
After this change, the company reports 859,902,420 NVX ordinary fully paid shares on issue. It also has 17,388,628 remaining NVXAD performance rights, 14,016,667 NVXAA options, 1,008,567 NVXAB share rights and 45,221,586 NVXAL convertible notes on issue.